The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.
NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:
- PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)
In addition, NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) U24 recipients from these FOAs:
- RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24)
- RFA-TR-16-021 Coordination Center for the CTSA Program (U24)
- RFA-TR-15-002 CTSA Network - Trial Innovation Centers (TICs) (U24)
- RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs)(U24)
NCATS expects to issue 1-4 awards for involvement with clinical studies and trials in support of COVID interventions, as well as providing clinical samples and assessing infectious or convalescent status.